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It is known that for achieving high affinity antibody responses, vaccines must be opti-
mized for antigen dose/density, and the prime/boost interval should be at least 4 weeks.
Similar knowledge is lacking for generating high avidity T-cell responses. The functional
avidity (FA) of T cells, describing responsiveness to peptide, is associated with the quality
of effector function and the protective capacity in vivo. Despite its importance, the FA is
rarely determined in T-cell vaccination studies. We addressed the question whether dif-
ferent time intervals for short-term homologous vaccinations impact the FA of CD8 T-cell
responses. Four-week instead of 2-week intervals between priming and boosting with
potent subunit vaccines in C57BL/6 mice did not improve FA. Equally, similar FA was
observed after vaccination with virus-like particles displaying low versus high antigen
densities. Interestingly, FA was stable in vivo but not in vitro, depending on the antigen
dose and the time interval since T-cell activation, as observed in murine monoclonal T
cells. Our findings suggest dynamic in vivo modulation for equal FA. We conclude that
low antigen density vaccines or a minimal 4-week prime/boost interval are not crucial
for the T-cell’s FA, in contrast to antibody responses.
Keywords: Avidity regulation  Functional avidity  Prime/boost  T-cell receptor affinity 
T-cell vaccination
 Additional supporting information may be found online in the Supporting Information sectionat the end of the article.
Introduction
It has long been known that B-cell responses employ affinity
maturation to optimize antibody affinity over time [1, 2]. Con-
sequently, most vaccine regimens are designed to induce B-cell
Correspondence: Prof. Daniel E. Speiser
e-mail: daniel.speiser@unil.ch
responses with favorable antibody affinity, by using vaccines with
well-chosen antigen doses/densities, and by vaccination with
prime/boost (P/B) intervals of at least 4 weeks. The situation
for improving the quality of T cells is much less clear [3].
The functional avidity (FA) describes the T-cell’s sensitivity for
peptide-MHC (pMHC) and correlates with biological functions
such as killing, cytokine production, and anti-viral protection [4].
Several studies showed that during a CD8 T-cell response, the
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clonality and the FA remains remarkably stable [5–9]. Other
studies demonstrated FA changes over time, in part due to shifts
in the clonal dominance and thus in the TCR usage [10, 11].
Even though TCR affinity and T cells’ FA are important cor-
relates of protection from disease [4, 12], it remains poorly
understood whether certain vaccine doses, formulations, or P/B
schemes induce T-cell responses with better affinity and FA. Some
researchers have primed with one vaccine, only to boost with a
different vaccine formulation optimized for CD8 T-cell responses
with enhanced FA [13]. Many studies investigating changes in
the FA of the peptide-specific CD8 T-cell response have focused
on altered peptide ligands to artificially modulate the TCR pool
recruited. Although the altered peptides were primarily designed
for improved peptide-MHC binding affinity, they often displayed
small but relevant alterations in TCR binding [14, 15]. How-
ever, changing epitopes from prime to boost and/or effector
phase preclude direct conclusions on eventual avidity matura-
tion because avidity differences may be due to fine specificity
differences.
The question as to whether avidity maturation occurs in vivo,
and if so can be improved by optimizing vaccination dosing and
scheduling, can be better addressed by using the same vaccine for-
mulation for sequential “homologous” vaccinations, focusing on
precisely the same epitope. There has been evidence from early
studies suggesting that using low antigen doses produced T cells
with higher avidity, compared to high dose [16–19]. However,
others have shown that it was the dose used for a boosting immu-
nization that was critical to achieve improved FA, with no differ-
ence after a single immunization [20] and a more recent study
found that CD8 T-cell FA was not altered by changes in vaccine
dose [21]. Therefore, it remains unclear exactly how changes in
peptide dose influences the FA of a peptide-specific T-cell response
to vaccination. Two studies investigating T-cell responses to infec-
tion with Listeria monocytogenes and LCMV, respectively, showed
evidence for avidity maturation [22, 23]. The latter study sug-
gested FA maturation during the first week of priming in a mono-
clonal CD8 T-cell population [23]. However, the practical question
remains open whether short-term homologous P/B vaccinations
with subunit vaccines can be optimized to achieve high FA T-cell
responses, through strategies analogous to vaccination for high
affinity antibody responses. Therefore, we used subunit vaccines
to investigate whether homologous vaccination with different P/B
intervals (2 vs. 4 weeks) or altered antigen density would impact
the FA of a peptide-specific CD8 T-cell response.
Results
Functional avidity (FA) was not improved
with a prolonged prime/boost (P/B) interval
Based on the knowledge of vaccination for antibody responses,
we wanted to investigate the effect of boosting at different
time points after an initial prime. It was of interest to deter-
mine whether the FA of CD8 T cells would be improved after
a 4-week delay compared to 2-week, as a minimal 4-week
interval is standard clinical practice for vaccinations induc-
ing antibody responses (https://www.cdc.gov/vaccines/hcp/acip-
recs/index.html). To address this question, WT mice were primed
s.c. with 20 µg of the potent subunit amphiphilic vaccine (Amph-
vaccine) containing the ovalbumin epitope, SIINFEKL, and cyclic
di-GMP, as an adjuvant for LN targeting (Fig. 1A) [24, 25]. A boost
vaccination of the same dose was given either 2 or 4 weeks follow-
ing the prime (Fig. 1B). Splenocytes were harvested 7 days follow-
ing the boost and directly plated in an IFN-γ ELISpot assay with
soluble peptide (Fig. 1C) to determine the peptide dose for the half
maximal response (EC50), reflecting the FA.When comparingmice
that received either a 2- or 4-week boost, there was no difference
in the mean EC50 (Fig. 1D). However, a 4-week boost improved
the quantity of peptide-specific CD8 T cells compared to the 2-
week boost (Fig. 1E, Supporting Information Fig. 1A). Despite
the increased number of tetramer positive CD8 T cells, FA was
not improved. The P/B regimen was also tested using an amph-
vaccine with the tyrosine-related peptide 2 (Trp2) (VYDFFVWL).
Similarly, we found no difference in EC50 between a 2- or 4-week
boost (Fig. 1F). Here, we found similar numbers of tetramer pos-
itive CD8 T cells (Fig. 1G, Supporting Information Fig. 1B). With
these two amph-vaccines, the mean EC50 of the IFN-γ response
was comparable between a 2- or 4-week boost. Thus, in contrast to
what is known for B-cell response-inducing vaccines, these results
indicate that delaying the second vaccination from 2 to 4 weeks
does not improve the FA of the peptide-specific T-cell response.
Vaccinations with virus-like particles (VLPs) coated
with different peptide densities do not affect the FA
A third subunit vaccine was used, composed of virus-like particles
(VLPs) containing type B CpG ODN as an adjuvant and SIINFEKL
peptide (Fig. 2A) [26]. We first compared the P/B regimen and
again found no difference in EC50 between a 2- or 4-week boost
(Fig. 2B). Using VLPs allowed us to investigate changing the anti-
gen density, as previous research has suggested that increased
antigen availability lowers the FA of the corresponding CD8 T
cells [16, 27]. Using VLPs with a range of SIINFEKL peptide densi-
ties (0.5–4-fold, Supporting Information Fig. 2), mice were immu-
nized s.c., boosted at 2 weeks with the same density as the prime,
and spleens were harvested 7 days following the boost for FA
assessment by IFN-γ ELISpot assay. There was no difference in
EC50 when comparing the different antigen densities (Fig. 2C).
The magnitude of the peptide-specific T-cell response between the
different VLP densities was also unchanged (Fig. 2C, Supporting
Information Fig. 1C). Therefore, the FA of the CD8 T-cell response
was not altered by vaccinations with different peptide densities.
Indeed, when testing the same regimen with mice immunized
with VLPs loaded with the gp33 peptide (KAVYNFATM) and a
10× difference between peptide densities, the FA remained the
same (Fig. 2D). These results indicate that responding CD8 T cells
have similar FA despite the P/B vaccinations with different peptide
densities.
C© 2019 The Authors. European Journal of Immunology published by
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Figure 1. Delayed boost vaccination does not
improve functional avidity (FA) of ovalbumin-
specific CD8 T cells. (A) Schematic of amph-vaccine
design. (B) WT mice were immunized s.c. at the
tail base with 50 µg amph-vaccine containing SIIN-
FEKL (ovalbumin) peptide and boosted with the
same dose at either 2- or 4-week following the
prime. Splenocytes were harvested 7 days follow-
ing last vaccination. (C) Representative wells from
one titration (performed in triplicates) of an IFN-γ
ELISpot assay. (D) A dose titration of SIINFEKL pep-
tide was used to determine FA, that is the pep-
tide dose (EC50) required for half maximal IFN-γ
ELISpot forming cells. The data are from a sin-
gle experiment representative of two independent
experiments (n = 3 mice/experiment). Blood was
taken 7 days following the boost and analyzed by
flow cytometry. Cells were gated on Kb-SIINFEKL
tetramer positive cells from CD8+CD3+ T cells, as
shown in Supporting Information Figure 1. Statisti-
cal analysis by unpaired t-test, *p < 0.05. (E) Mice
were immunized s.c. at the tail base with 50 µg
of amph-vaccine containing VYDFFVWL (Trp2) pep-
tide, and the ELISpot titrated with VYDFFVWL pep-
tide. Bloodwas taken 7 days following the boost and
analyzed by flow cytometry. Cells were gated on Kb-
VYDFFVWL tetramer positive cells from CD8+CD3+
T cells. The data are combined from two indepen-
dent experiments (n = 2 mice/experiment). Statis-
tical analysis by unpaired t-test. All values show
mean and SD.
FA improves in vitro with increased time
after activation
The second half of our study focused on monoclonal T cells, to
investigate TCR affinity-independent FA regulation in response to
homologous peptide vaccination. It has previously been shown
that a monoclonal T-cell population was able to undertake avid-
ity maturation during the first few days after LCMV infection,
based on TCR affinity-independent FA regulation [23]. We won-
dered if there was an early modulation of the T- cell response that
eventually “leveled out” to a moderate FA that remained stable.
To determine whether this may occur with a monoclonal T-cell
population, we set up in vitro cultures using monoclonal OT-1 T
cells specific for SIINFEKL presented on H2-Kb. OT-1 splenocytes
were activated with a range of SIINFEKL peptide concentrations
(0.1 to 1000 nM) and cultured with either IL-2 alone, or IL-2
with IL-7 and IL-15 to improve viability, which was required for
longer cultures (day 10). Cells were harvested at days 4, 6, and 10
postactivation to assess FA by IFN-γ ELISpot assay, and cell surface
receptor expression was evaluated concurrently by flow cytometry
analysis. We found that the EC50 improved with time by over one
log, an effect that was statistically significant when the cells had
been activated with 1 µM peptide, and with the same trend for
all other peptide doses tested (Fig. 3A). The addition of IL-7 and
IL-15 for cell survival did not impact the FA observed. Most of
the FA improvement occurred between day 6 and day 10. These
results are comparable to our previous findings showing that the
FA of human T-cell clones was related to the cellular activation
status in vitro. Supporting Information Fig. 3 shows these previ-
ously published data [28] in more detail, where peptide-specific
CD8 T-cell clones were cultured from the PBMC of vaccinated
melanoma patients. These results emphasize that human CD8 T-
cell clones consistently increase their FA from day 10 to day 15
after restimulation, in parallel to the steady reduction of their
activation state [28].
Besides the influence of time postactivation on FA, we also
found aminor but consistent effect of the peptide dose used to acti-
vate OT-1, with decreasing EC50 as peptide dose increases (Fig. 3A
and B). As expected, we observed regulation of coreceptors with
rapid activation, as seen by the increased expression of CD69 rela-
tive to unstimulated cells, as well as a trend for increased PD-1, in a
dose-dependent manner (Fig. 3C, Supporting Information Fig. 4).
C© 2019 The Authors. European Journal of Immunology published by
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Figure 2. Similar FA induced by vaccinations with VLPs despite different prime/boost (P/B) interval or antigen density. (A) Schematic of VLP
vaccine design. (B) WT mice were immunized s.c. at the tail base with 50 µg VLP peptide displaying SIINFEKL and boosted with the same dose at
either 2- or 4-week following the prime. Splenocytes were harvested 7 days following last vaccination and analyzed in an IFN-γ ELISpot assay with
titrated SIINFEKL peptide. Statistical analysis by unpaired t-test. The data are combined from two independent experiments with different VLP
densities used (n = 1–2 mice per density/experiment). (C) Vaccination with VLPs displaying SIINFEKL peptide at peptide densities of 0.5, 1, 2, or 4×,
respectively. Schedule as above, with a boost at 2 weeks. Statistical analysis by one-way ANOVA with Bonferroni post-test. All comparisons were
not significant. Blood was taken 7 days following the boost and analyzed by flow cytometry. Cells were gated on Kb-SIINFEKL tetramer positive
cells from CD8+CD3+ T cells, as shown in Supporting Information Figure 1. The data are combined from two independent experiments (n = 2 mice
per density/experiment). (D) Vaccination with VLPs displaying KAVYNFATM (LCMV gp33) peptide. Schedule as above. Analysis with an ELISpot
assay with titrated KAVYNFATM peptide. The data are combined from two independent experiments (n = 2 mice/experiment). Statistical analysis
by unpaired t-test. All values show mean and SD. *p < 0.05.
Previous studies have shown that the strength of stimulus will
cause a concentration dependent downregulation of TCRβ [29],
which is known to directly impact the FA [30]. As anticipated,
we saw that higher peptide concentrations induced stronger TCRβ
downregulation, followed by TCRβ increase over time (Fig. 3D).
FA remains stable in vivo
We then wanted to know whether these early FA changes of a
monoclonal population observed in vitro were similarly found in
vivo early after vaccination. Purified CD8 OT-1 cells were adop-
tively transferred into WT mice that were immunized with CpG
and SIINFEKL (the same peptide as used in vitro) 6 h following
transfer. Cells were harvested at various days postactivation to
assess FA by IFN-γ ELISpot assay. Interestingly, when comparing
the earlier (days 2 and 6) and the later days (days 8 and 12)
postimmunization, the EC50 remained unchanged (Fig. 4A).
For many years, we have been characterizing the FA of CD8
T cells in healthy volunteers and cancer patients. We and others
have shown that in chronic antigen exposure, long-term antigen-
specific CD8 T cells also demonstrate remarkable FA stability and
clonotypic stability [5–9]. In addition, here we studied a
melanoma patient who had developed a strong immune response
by expansion of HLA-A2/NY-ESO-1-specific CD8 T cells, as
described previously [31]. T-cell clones were generated from
C© 2019 The Authors. European Journal of Immunology published by
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Figure 3. FA increases in vitro with
time after peptide activation. (A)
Splenocytes from untreated OT-1
mice were cultured with a range
of SIINFEKL peptide doses (0.1 to
1000 nM). Cells were collected at days
4, 6, and 10 postactivation for IFN-γ
ELISpot assay with titrated peptide
concentrations (x-axis) and parallel
flow cytometry analysis. Cells were
cultured with hIL-2 alone, or hIL-2
with hIL-7 and hIL-15 as depicted
in orange. The data are com-
bined from three independent exper-
iments with triplicates/experiment,
with representative titration curves
from one. Statistical analysis by two-
way ANOVA with Bonferroni post-
test. (B) Correlations of FA with the
peptide concentration used for in
vitro activation of OT-1 splenocytes.
(C-D) Cell surface expression of CD69,
PD-1, and TCRβ determined by flow
cytometry and presented as geomet-
ric MFI (gMFI) fold change compared
to unstimulated control cells. The
data are combined from two to four
independent experiments with one
sample/experiment. Statistical anal-
ysis by two-way ANOVA with Bon-
ferroni post-test comparing time. All
values show mean and SD. *p < 0.05,
**p < 0.01, ***p < 0.001.
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Figure 4. FA remains stable in vivo. (A) Purified CD8+ OT-1 cells (1 × 106) were adoptively transferred into WT mice. Six hours following transfer,
mice were vaccinated s.c. at the tail base with 10 µg SIINFEKL and 50 µg CpG 7909. Splenocytes were harvested at various time points and
analyzed in an IFN-γ ELISpot assay. Left: Representative titration curves. Right: The data are combined from two independent experiments (n = 2–3
mice/experiment, mean values ± SD). Statistical analysis by one-way ANOVA with Bonferroni post-test. There were no statistically significant
differences. (B) Human HLA-A2/NY-ESO-I-specific CD8 T-cell clones were generated using PBMC obtained in the years 2001 and 2005 from a
melanoma patient. The clones were tested in cytotoxicity assays using T2 target cells pulsed with titrated NY-ESO-1 peptide to determine the
FA (EC50). The data are combined from three to four independent experiments with triplicates/experiment (n = 8–10 clones/experiment, mean
values ± SD). Statistical analysis by Mann–Whitney test.
PBMC taken at two different collection times, and their FA was
determined. Interestingly, we found similar EC50 values with the
clones generated from PBMC obtained in the year 2001, as com-
pared to those of the year 2005 (Fig. 4B). The repertoire at the
two time points showed sharing of several clonotypes and TCR β-
chain subfamilies (Supporting Information Table 1). There was no
evidence of enrichment of higher affinity T cells. This stability is
in line with the majority of findings in the literature, showing that
viral antigen-specific CD8 T-cell responses in vivo have remarkably
stable FA [8, 9].
In summary, our in vitro data showed increased FA with
time after activation and confirmed findings in the literature
showing that FA is modulated by TCR affinity-independent
regulators [23, 32, 33]. However in vivo, we observed FA stability
despite different P/B intervals and peptide densities, and found
FA stability over time; suggesting that FA regulators are constantly
active in vivo to assure stable and equal FA.
Discussion
Using subunit vaccines, we addressed the impact of homolo-
gous P/B regimens and different antigen density on the FA of
peptide-specific CD8 T cells. Despite its practical importance, it
has remained unclear whether the length of the P/B interval is
critical for optimal FA for a T-cell response to a given peptide
antigen [34]. In clinical practice, a short interval would be easier,
as compared to the minimal 4-week period that has been widely
accepted for inducing high affinity antibody responses. Whether
this would be applicable to the T-cell response has yet to be deter-
mined, specifically with homologous vaccination. To investigate,
we assessed both 2- and 4-week boosting after prime, with the pre-
diction that a 2-week boost would be suboptimal. Interestingly, we
found no difference in the FA of the peptide-specific CD8 T-cell
response, indicating that the 4-week interval does not mediate a
more favorable FA.
The FA depends on the TCR affinity to the pMHC. In murine
and human CD8 T-cell responses, some studies showed increas-
ing dominance of cells bearing TCRs mediating stronger T-cell
functions [10, 35, 36]. Thus, changes in clonal dominance may
impact on the FA. While most studies relied on partial char-
acterization of the involved TCRs [22], full characterization of
TCR-α and -β chains and the role of CD8 binding showed clonal
shifts in some studies [37, 38], in contrast to stability in oth-
ers [5–8]. Shifts of codominant clones usually occur over longer
periods of time, typically between the initial T-cell response
and the memory response many weeks later [10, 39, 40]. Our
study is not focused on memory (long-term) responses, but
on the generation of the primary immune response. In this
short time-frame, one would not expect clonotypes (with TCRs
mediating similar function) to show early short-term selection.
Even after long intervals, the TCR repertoire and consequently the
FA can remain highly stable as found in some models or patients
[5, 7, 37], whereas long-term selective outgrowth of clonotypes
C© 2019 The Authors. European Journal of Immunology published by
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with different TCR affinity and different FA may occur in other
settings [9, 41].
It has been suggested that the use of low antigen dose may
achieve high FA responses [16, 19]. A frequently cited study with
DCs loaded with high versus low peptide concentrations showed
more favorable FA induced by low peptide [17]. However,
another study found that DCs loaded with higher antigen did not
impact on FA, whereas it improved T-cell expansion [42]. In the
context of peptide vaccination, one study found that low antigen
dose improved the FA of CD4 T cells, but this did not extend
to CD8 T cells [21]. To vary antigen dose in vivo, we designed
a novel approach, consisting of VLPs decorated with different
peptide densities. The presumption made is that high peptide
density gives rise to higher peptide presentation by APCs in vivo.
Due to the technical challenges involved, the peptide density on
the surface of DCs is rarely determined including the study cited
above [17]. Moreover, DC vaccination is not broadly applicable
and using low peptide doses makes it difficult to verify peptide
density in vivo. We used VLPs with different peptide density
within a 10-fold range to reflect what can practically be achieved
in vaccines with potential clinical application. Interestingly, the FA
was not improved by vaccination with low peptide density VLPs.
It is worth noting that the stable FA observed is within the
context of homologous subunit vaccination; different results may
be obtained with other types of immunization, and/or when using
different vaccines for P/B. Using heterologous P/B vaccination,
several studies have shown that different vaccine formulations and
epitopes used for boosting can achieve improved FA [13–15, 43].
However, boosting with a vaccine that differs from the prime
biases the T-cell pool and may select for those with higher affinity,
reflecting the differences of the vaccines used rather than endoge-
nous avidity maturation alone. Furthermore, our study did not
aim at optimizing the magnitude of the CD8 T-cell response as it
does not necessarily equal protective capacity, at least not when
comparing immunization strategies that all reach high frequen-
cies [44]. While we focused on the FA in response to subunit
vaccination, other studies analyzed the FA in response to infec-
tions. Slifka et al. has shown FA maturation in a T-cell response
to LCMV infection [23], and other studies used L. monocytogenes
and influenza infections to demonstrate T-cell affinity matura-
tion through clonal shifts [10, 22]. The increased inflammation
that occurs during infection may impact on the FA, as it has been
shown that effector functions were enhanced in both low and high
affinity T cells in mice that were administered peptide-pulsed DCs
with a concurrent L. monocytogenes infection, compared to no
infection [45].
A central finding of our study is that the FA of OT-1 cells under-
went considerable changes in vitro, as opposed to the observed FA
stability in vivo. Since these monoclonal T cells are controlled
through a single type of TCR, the FA differences observed in vitro
are TCR affinity independent. FA changes in vitro depended on the
timing postactivation, and the antigen concentration used, which
both impact the activation-dependent changes in receptor levels
involved in the immune synapse, and consequently the FA. Simi-
lar activation state-dependent FA changes can also be observed in
human CD8 T-cell clones analyzed in vitro [28]. These results also
point to an important methodological aspect: in order to obtain
reproducible FA data, T-cell clones must always be analyzed after
the same number of days since their last restimulation. The recent
introduction of Koff-rate measurement using new generation fluo-
rescent tetramers [28, 46] represents clear progress in the devel-
opment of new methods to assess T-cell avidity. Importantly, Koff-
rate data is independent of activation and also independent of
synapse molecules and coreceptors (besides CD8). While these
techniques are excellent for assessing monoclonal T cells, they are
unfortunately not yet satisfactory for the characterization of the
complex natural polyclonal T-cell responses.
We think that the remarkable FA stability observed in vivo
after early peptide vaccination may involve constant synapse reg-
ulation. Synapse alterations are more flexible and, thus, more
prominent as opposed to TCR affinity changes (i.e. clonal shifts),
particularly for rapid avidity regulation, which is likely involved
for keeping FA stable in vivo. There are multiple receptor-ligand
pairs in the immune synapse that may impact the FA [33, 47, 48]
such as regulatory receptors like PD-1. One study used a poxvirus
to infect APCs to express a triad of ICAM-1, LFA-3 and CD80, which
led to enhanced high avidity CD8 T cells in vivo, both in number
and function. This improvement was observed in both primary
and secondary responses [49]. Many excellent studies have char-
acterized the various components of the complex synapse mech-
anisms [49–51]. Nevertheless, it is probably still a long way until
one can quantify the roles and contributions of each component
and, thus, fully understand how FA is regulated by the synapse.
The potential flexibility of synaptic components to alter FA in
vivo may have the aim to give a close-to-equal chance to T cells
with different affinity TCRs, at least for those within a relatively
narrow affinity range mediating equal function [52]. A powerful
T-cell response usually involves broad polyclonal involvement, to
have many T cells participating in an epitope-specific response.
Indeed, polyclonality has been identified as a correlate of protec-
tion [53, 54]. It seems possible that FA regulation and stability is
required to avoid major selective outgrowth of very few clones at
the expense of most others. Modulation for equal FA in vivo may
also apply to T cells with the same TCR, to compensate the conse-
quences of their varying differentiation and activation states (e.g.
by different degrees of TCR downregulation) that have the poten-
tial to alter their functionality. Conceivably, modulation occurs
in such a way that T cells have equal functional interactions with
cells presenting cognate antigen, irrespective of their levels of acti-
vation and differentiation.
We conclude that subunit vaccination induces CD8 T-cell
responses with in vivo stable FA over time, in contrast to affin-
ity maturation observed in antibody responses. This suggests that
it is inconsequential to choose 2- or 4-week intervals, or a partic-
ular antigen density on vaccine particles. For clinicians, this may
be welcome news as it implies that 2-week boosting is acceptable,
thereby, greatly reducing the downtime required between immu-
nizations, which often must be repeated multiple times for sus-
tained T-cell responses. Our results advocate for a T-cell popula-
tion capable of adapting FA to ensure equal efficiency in vivo.
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Materials and methods
Mice
C57BL/6JOlaHsd mice were purchased from Envigo (Bicester,
UK). OT-1 mice were originally from The Jackson Laboratory
and bred in-house. All animal experiments were approved by the
Veterinary Authority of the Swiss canton Vaud and performed in
accordance with Swiss ethical guidelines. Mice were age matched,
female and at least 6 weeks old at the beginning of the experiment,
and maintained in conventional facilities at the Epalinges site of
the University of Lausanne (UNIL).
Vaccines
Mice were treated with 10 µg of SIINFEKL peptide (in-house
peptide facility) with 50 µg of CpG oligodeoxynucleotide 7909
(CpG ODN). Treatments were injected at the tail base s.c. in a
total volume of 100 µL. Amphiphilic vaccines contained 20 µg of
SIINFEKL or 20 µg of VYDFFVWL, and 25 µg of cyclic di-GMP
as an adjuvant (Amph-vaccine). Virus-like particles (VLPs) were
produced with the bacteriophage Qβ protein, and packaged with
the type B CpG ODN 1668 (1.125 µg per 20 µg Qβ), adminis-
tered at a dose of 50 µg/mouse. The VLPs were coupled with
different excess of the linker SMPH to achieve different sur-
face peptide densities. A 4× excess of SIINFEKLGGC-OH pep-
tide (Pepscan) was then bound to the SMPH, or 4× excess of
KAVYNFATMGGC-OH (LCMV gp33) peptide (Pepscan, Lelystad,
The Netherlands).
ELISpot assay
FA was always assessed 7 days after the last boost to compare
immunizations. Splenocytes were plated in a range of concen-
trations (2 × 103 to 1 × 105/well) on Multiscreen HTS plates
(Merck, NJ, USA) using the mouse IFN-γ ELISpot BASIC (ALP)
kit to detect murine IFN-γ (Mabtech, Stockholm, Sweden). Cells
were stimulated with titrated soluble peptide. As a positive con-
trol, cells were stimulated with PMA 50 ng/mL and Ionomycin
500 ng/mL (both Sigma-Aldrich, St. Louis, MI). Background from
control wells (unstimulated cells) were subtracted from the spot
forming units counts. Counts were normalized to graph as a per-
centage of IFN-γ producing cells and nonlinear regression curves
were used to calculate EC50.
Adoptive transfer of OT-1 cells
CD8 T cells were purified from naive OT-1 splenocytes using the
EasySepTM Mouse CD8 T-cell Isolation kit (StemCell, Vancouver,
Canada). A total of 1 × 106 purified cells were transferred into
WT mice and injected i.v.
In vitro stimulation of OT-1 cells
Splenocytes were stimulated with various doses of soluble SIIN-
FEKL peptide (0.1 to 1000 nM) and incubated at 37°C in 10%
FCS, 5 mg/mL penicillin, 5 mg/mL streptomycin, 0.05 mM 2-ME,
10 mM HEPES, and 1 mM sodium pyruvate (all Invitrogen, CA,
USA) in RPMI (cRPMI). Cells were split on day 4, following peptide
stimulation and 20 U/mL of hIL-2 (Roche) was added to each well.
Long-term cultures were split every other day, starting from day
2, into cRPMI with 10 U/mL of hIL-2, 10 ng/mL of hIL-7 (Miltenyi
Biotec, Bergisch Gladbach, Germany) and 10 ng/mL of hIL-15
(Peprotech, Rehovot, Israel). Unstimulated cells were cultured in
the same conditions without peptide and were used as controls.
Flow cytometry
Single cell suspensions were resuspended in FACS buffer (PBS
with 10 mM EDTA, 2% FBS) before staining with the follow-
ing antibodies: CD3 (17A2) that was prepared in-house, PD-1
(29F.11A12), CD8 (53–6.7) from Biolegend and TCRβ (H57.597),
CD69 (H1.2F3) from eBioscience. Fresh blood from mice was
lysed with red blood cell lysis buffer (in-house) and washed
twice with FACS buffer before staining as above. Peptide/H2-Kb
tetramers were made in-house. Dead cells were excluded as
staining positive with LIVE/DEADTM Fixable Aqua Dead (Thermo
Fisher Scientific, Waltham, MA). Cells were washed and resus-
pended in FACS buffer. Acquisition was performed on a BD LSRII
SORP (Becton Dickinson, NJ, USA) or a BD LSR Fortessa SORP
(Becton Dickinson) and data were analyzed using FlowJo version
10.3 (Tree Star). All experiments were performed according
to guidelines for the use of flow cytometry and cell sorting in
immunological studies [55].
Melanoma patients and human CD8 T cells
Melanoma patients provided written informed consent and par-
ticipated in clinical investigation protocols of the Ludwig Institute
for Cancer Research (LICR), approved by the Institutional Review
Boards and the LICR Protocol Review Committee. Blood samples
were collected and processed as previously described [31]. CD8 T
cells were sorted and cloned by limiting dilution and expanded,
and the FA was determined by peptide titration killing assays as
previously detailed [31].
Statistics
Statistical analyses were performed with GraphPad Prism 8. Num-
ber of spot forming units were normalized and EC50 values
were calculated using nonlinear regression curves. Normality was
assessed using the Shapiro–Wilk test, with data having passed the
normality check. Therefore, statistical evaluation was by unpaired
t-test, one-way or two-way ANOVAwith the Bonferroni correction.
Patient data were analyzed by the Mann–Whitney test. Differences
of p < 0.05 were deemed statistically significant.
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